deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07285902

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of HRS9531 Injection Versus Semaglutide Injection in Subjects With Obesity

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Conditions Obesity
Interventions HRS9531 injection Semaglutide Injection
Updated 2 times since 2026 Last updated: Feb 26, 2026 Started: Dec 25, 2025 Primary completion: Mar 31, 2027 Completion: Mar 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Obesity and is currently ongoing. Fujian Shengdi Pharmaceutical Co., Ltd. leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshotRecruiting~Feb 2026 – present · 7 months · monthly snapshotActive Not Recruiting

Change History

2 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  2. Jan 2026 — Feb 2026 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fujian Shengdi Pharmaceutical Co., Ltd.
Data source: Fujian Shengdi Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations